Patents by Inventor Jeffrey C. Pelletier

Jeffrey C. Pelletier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240067651
    Abstract: Disclosed are prodrugs of myeloperoxidase (MPO) inhibitors, methods of treating MPO related disorders, e.g., multiple system atrophy, amyotrophic lateral sclerosis, and Huntington's disease, and methods of neuroprotection, which include administering to a patient in need thereof the prodrugs, pharmaceutical compositions including the prodrugs, and kits including the pharmaceutical compositions and instructions for use.
    Type: Application
    Filed: October 9, 2020
    Publication date: February 29, 2024
    Inventors: Gene M. DUBOWCHIK, Joseph Theodore LUNDQUIST, IV, Melody A. MCWHERTER, Jeffrey C. PELLETIER, Allen B. REITZ, Eric STROBEL, Yan ZHANG
  • Patent number: 10780084
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: September 22, 2020
    Assignees: YALE UNIVERSITY, KLEO PHARMACEUTICALS, INC.
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch
  • Publication number: 20190192497
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 27, 2019
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch
  • Patent number: 7582636
    Abstract: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Joseph T. Lundquist, IV, Jeffrey C. Pelletier, Matthew D. Vera
  • Patent number: 7582634
    Abstract: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Jeffrey C. Pelletier, John F. Rogers, Jr.
  • Patent number: 7538113
    Abstract: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: May 26, 2009
    Assignee: Wyeth
    Inventor: Jeffrey C. Pelletier
  • Patent number: 7534796
    Abstract: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: May 19, 2009
    Assignee: Wyeth
    Inventors: Jeffrey C. Pelletier, John F. Rogers, Jr.
  • Patent number: 7531542
    Abstract: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: May 12, 2009
    Assignee: Wyeth
    Inventors: Daniel M. Green, Diane B. Hauze, Charles W. Mann, Jeffrey C. Pelletier, Matthew D. Vera
  • Publication number: 20020037907
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: July 12, 2001
    Publication date: March 28, 2002
    Applicant: American Home Products Corporation
    Inventors: Robert J. Steffan, Mark A. Ashwell, Jeffrey C. Pelletier, William R. Solvibile, Edward M. Matelan
  • Patent number: 6048853
    Abstract: Substituted 1-arylphthalazine compositions with the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independentlya) H,b) HO,c) R.sup.11 O--,d) halogen,e) C1-C3-alkyl,f) CF.sub.3,g) R.sup.12 CO.sub.2 --, orh) R.sup.12 CONH--;R.sup.1 and R.sup.2, or R.sup.2 and R.sup.3, or R.sup.3 and R.sup.4 can be taken together to bea) --OCH.sub.2 O--, orb) --OCH.sub.2 CH.sub.2 O--;R.sup.5 isa) H,b) C1-C6-alkyl,c) C3-C6-alkenyl,d) C3-C6-alkynyl,e) C3-C6-cycloalkyl,f) phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents selected from the group consisting of C1-C3-alky, halogen, R.sup.12 HN--, R.sup.12 O--, CF.sub.3 --, R.sup.13 SO.sub.2 -- and CO.sub.2 R.sup.12, org) phenyl-C1-C3-alkyl or substituted phenyl-C1-C3-alkyl, wherein the phenyl is substituted with one or two substituents selected from the group consisting of C1-C3-alkyl, halogen, R.sup.12 HN--, R.sup.12 O--, CF.sub.3 --, R.sup.13 SO.sub.2 -- and --CO.sub.2 R.sup.12 ;R.sup.6 isa) R.sup.10 R.sup.11 N--,b) R.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: April 11, 2000
    Assignee: Bearsden Bio, Inc.
    Inventors: Mark A. Collins, Jeffrey C. Pelletier
  • Patent number: 5716956
    Abstract: Substituted dihydrophthalazine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: February 10, 1998
    Assignee: Bearsden Bearsden Bio, Inc.
    Inventor: Jeffrey C. Pelletier
  • Patent number: 5332726
    Abstract: This invention relates to novel peptide and pseudopeptide derivatives and analogs of aspartic acid which are useful as inhibitors of platelet aggregation and thrombus formation in mammalian blood, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.
    Type: Grant
    Filed: March 30, 1992
    Date of Patent: July 26, 1994
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Scott I. Klein, Bruce F. Molino, Mark Czekaj, Charles Gardner, Michael R. Becker, Jeffrey M. Dener, Jeffrey C. Pelletier
  • Patent number: 5063230
    Abstract: This invention relates to a series of bicyclic benzomonoazacyclic carboxamide compounds of the general formula: ##STR1## Where Z is tertiary amine, which are useful for the method of treating patients suffering from gastrointestinal disorders, and of pharmaceutical composition including an effective 5HT3 - antagonists amount of said compounds therein.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: November 5, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Jeffrey C. Pelletier, Raymond D. Youssefyeh, Henry F. Campbell
  • Patent number: 4952562
    Abstract: Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.
    Type: Grant
    Filed: September 29, 1989
    Date of Patent: August 28, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Scott I. Klein, Bruce F. Molino, Mark Czekaj, Charles J. Gardner, Jeffrey C. Pelletier
  • Patent number: 4935511
    Abstract: This invention relates to benzoxazine and benzoxazepine carboxamide compounds which exhibit 5-HT.sub.3 antagonist properties including CNS, anti-emetic and gastric prokinetic activity and which are void of any significant D.sub.2 receptor binding affinity. This invention also relates to pharmaceutical compositions and methods for the treatment of gastrointestinal and mental disorders using said compounds.
    Type: Grant
    Filed: September 26, 1989
    Date of Patent: June 19, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Raymond D. Youssefyeh, Jeffrey C. Pelletier, Henry F. Campbell
  • Patent number: 4933445
    Abstract: This invention relates to heteroazabenzo-bicyclic substituted carboxamide compounds of the formula: ##STR1## where W is O, S or NR.sub.5 andZ is ##STR2## 3-quinuclidine, 4-quinuclidine,4-(1-azabicyclo[3.3.1]nonane),3-(9-methylazabicyclo[3.3.1]nonane),7-(3-oxo-9-methylazabicyclo[3.3.1]nonane) or4-[3-methoxy-1-(3-[4-fluorophenoxy[propyl)piperidine];which exhibit 5-HT.sub.3 antagonist properties including CNS, anti-emetic and gastric prokinetic activity. This invention further relates to pharmaceutical compositions and methods for the treatment of the above disorders.
    Type: Grant
    Filed: November 29, 1988
    Date of Patent: June 12, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Jeffrey C. Pelletier, Raymond D. Youssefyeh, Henry F. Campbell
  • Patent number: 4920219
    Abstract: Certain specific substituted azabicyclic carboxiamides and their valuable use as 5-HT3 antagonists having CNS and gastric prokenetic activity void of any D.sub.2 receptor binding properties are disclosed.
    Type: Grant
    Filed: November 29, 1988
    Date of Patent: April 24, 1990
    Assignee: Rorer Pharmaceutical Corp.
    Inventors: Jeffrey C. Pelletier, Raymond D. Youssefyeh, Henry F. Campbell
  • Patent number: 4920227
    Abstract: Certain specific substituted benzobicyclic carboxamides and their valuable use as 5-HT3 antagonists having CNS and gastric prokenetic activity void of any significant D.sub.2 receptor binding activity are disclosed.
    Type: Grant
    Filed: November 29, 1988
    Date of Patent: April 24, 1990
    Assignee: Rorer Pharmaceutical Corp.
    Inventors: Jeffrey C. Pelletier, Raymond D. Youssefyeh, Henry F. Campbell